7Baggers

Esperion Therapeutics, Inc
(NASDAQ:ESPR) 

ESPR stock logo

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic aci...

Founded: 1998
Full Time Employees: 193
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 
                                                 
      revenues:
    		                                             
      product sales
    		43,391,000 40,659,000 40,274,000 34,913,000 31,561,000 31,106,000 28,302,000 24,756,000 20,760,000 20,251,000 20,293,000 17,031,000 14,967,000 13,964,000 13,578,000 13,354,000 12,192,000 10,895,000 10,610,000 6,350,000 8,167,000 3,331,000 609,000 858,000                      
      collaboration revenue
    		36,713,000 46,650,000 42,111,000 30,082,000 37,552,000 20,526,000 45,532,000 112,979,000 11,490,000 13,718,000 5,493,000 7,298,000 3,851,000 5,016,000 5,263,000 5,482,000 3,209,000 3,514,000 30,049,000 1,628,000 1,471,000 502,000 211,627,000 982,000 982,000 981,000 982,000 145,419,000                  
      total revenues
    		80,104,000 87,309,000 82,385,000 64,995,000 69,113,000 51,632,000 73,834,000 137,735,000 32,250,000 33,969,000 25,786,000 24,329,000 18,818,000 18,980,000 18,841,000 18,836,000 15,401,000 14,409,000 40,659,000 7,978,000 9,638,000 3,833,000 212,236,000 1,840,000 982,000 981,000 982,000 145,419,000                  
      yoy
    		15.90% 69.10% 11.58% -52.81% 114.30% 52.00% 186.33% 466.14% 71.38% 78.97% 36.86% 29.16% 22.19% 31.72% -53.66% 136.10% 59.79% 275.92% -80.84% 333.59% 881.47% 290.72% 21512.63% -98.73%                      
      qoq
    		-8.25% 5.98% 26.76% -5.96% 33.86% -30.07% -46.39% 327.09% -5.06% 31.73% 5.99% 29.29% -0.85% 0.74% 0.03% 22.30% 6.88% -64.56% 409.64% -17.22% 151.45% -98.19% 11434.57% 87.37% 0.10% -0.10% -99.32%                   
      operating expenses:
    		                                             
      cost of goods sold
    		34,573,000 41,289,000 28,543,000 31,538,000 25,631,000 17,286,000 15,609,000 10,075,000 11,452,000 13,377,000 6,786,000 11,652,000 4,160,000 6,506,000 9,176,000 7,125,000 5,075,000 5,558,000 1,800,000 1,784,000 1,688,000 275,000 398,000 31,000                      
      research and development
    		8,988,000 14,131,000 7,238,000 12,557,000 10,977,000 10,397,000 11,461,000 13,403,000 17,742,000 14,885,000 22,099,000 31,381,000 33,033,000 29,143,000 32,432,000 24,319,000 27,616,000 25,331,000 25,074,000 27,954,000 41,964,000 35,283,000 34,987,000 34,702,000 38,234,000 48,281,000 42,788,000 46,308,000 41,551,000 39,524,000 40,940,000 40,056,000 38,248,000 35,860,000 13,498,000 9,698,000 9,791,000 7,247,000 7,209,000 7,390,000 7,174,000 6,528,000 5,400,000 3,482,673 3,100,422 
      selling, general and administrative
    		43,124,000 41,848,000 39,509,000 42,996,000 36,925,000 39,975,000 44,185,000 41,988,000 45,423,000 33,240,000 33,959,000 29,901,000 24,138,000 24,954,000 29,609,000 30,381,000 38,338,000 39,265,000 46,318,000 61,064,000 61,555,000 48,826,000 47,681,000 41,553,000                      
      total operating expenses
    		86,685,000 97,268,000 75,290,000 87,091,000 73,533,000 67,658,000 71,255,000 65,466,000 74,617,000 61,502,000 62,844,000 72,934,000 61,331,000 60,603,000 71,217,000 61,825,000 71,029,000 70,154,000 73,192,000 90,802,000 105,207,000 84,384,000 83,066,000 76,286,000 59,946,000 66,749,000 56,280,000 58,490,000 50,562,000 46,480,000 46,894,000 45,737,000 43,660,000 40,889,000 17,712,000 14,331,000 14,822,000 12,919,000 12,462,000 11,425,000 9,700,000 9,254,000 7,890,000 5,406,823 4,271,847 
      income from operations
    		-6,581,000 -9,959,000 7,095,000 -22,096,000 -4,420,000 -16,026,000 2,579,000 72,269,000 -42,367,000 -27,533,000 -37,058,000 -48,605,000 -42,513,000 -41,623,000 -52,376,000 -42,989,000 -55,628,000 -55,745,000 -32,533,000 -82,824,000 -95,569,000 -80,551,000 129,170,000 -74,446,000 -58,964,000 -65,768,000 -55,298,000                   
      yoy
    		48.89% -37.86% 175.11% -130.57% -89.57% -41.79% -106.96% -248.69% -0.34% -33.85% -29.25% 13.06% -23.58% -25.33% 60.99% -48.10% -41.79% -30.80% -125.19% 11.25% 62.08% 22.48% -333.59%                       
      qoq
    		-33.92% -240.37% -132.11% 399.91% -72.42% -721.40% -96.43% -270.58% 53.88% -25.70% -23.76% 14.33% 2.14% -20.53% 21.84% -22.72% -0.21% 71.35% -60.72% -13.34% 18.64% -162.36% -273.51% 26.26% -10.35% 18.93%                    
      operating margin %
    		-8.22% -11.41% 8.61% -34.00% -6.40% -31.04% 3.49% 52.47% -131.37% -81.05% -143.71% -199.78% -225.92% -219.30% -277.99% -228.23% -361.20% -386.88% -80.01% -1038.15% -991.59% -2101.51% 60.86% -4045.98% -6004.48% -6704.18% -5631.16% 0% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      interest expense
    		-19,798,000 -22,051,000 -20,486,000 -19,431,000 -16,422,000 -15,082,000 -13,723,000 -14,024,000 -15,057,000 -14,995,000 -14,537,000 -14,387,000 -14,329,000 -14,153,000 -14,266,000 -14,062,000 -13,430,000 -13,654,000 -11,144,000 -8,125,000 -8,931,000 -4,928,000 -4,640,000 -4,171,000 -4,124,000 -3,996,000                    
      other income
    		1,183,000 677,000 666,000 1,072,000 1,207,000 1,584,000 2,454,000 2,777,000 1,080,000 1,278,000 1,660,000 1,273,000 1,355,000 659,000 318,000 320,000 3,939,000 13,000 9,000 14,000 24,000 42,000 81,000 368,000 1,142,000 1,387,000 1,077,000 450,000 651,000 750,000 764,000 562,000 378,000 415,000 399,000 395,000 347,000 248,000 202,000 93,000 29,000 17,000 16,000 168,389 4,035 
      net income
    		-25,196,000 -31,333,000 -12,725,000 -40,455,000 -21,318,000 -29,524,000 -61,925,000 61,022,000 -56,344,000 -41,250,000 -49,935,000 -61,719,000 -55,487,000 -55,117,000 -66,324,000 -56,731,000 -65,119,000 -69,386,000 -43,668,000 -90,935,000 -104,476,000 -85,437,000 124,611,000 -78,249,000 -61,946,000 -68,377,000 -54,221,000 87,379,000 -49,911,000 -45,730,000 -46,130,000 -45,219,000 -43,337,000 -40,541,000 -17,402,000 -14,035,000 -14,585,000 -12,801,000 -12,395,000 -11,466,000 -9,806,000 -9,238,000 -7,874,000 -5,238,434 -6,921,076 
      yoy
    		18.19% 6.13% -79.45% -166.30% -62.16% -28.43% 24.01% -198.87% 1.54% -25.16% -24.71% 8.79% -14.79% -20.56% 51.88% -37.61% -37.67% -18.79% -135.04% 16.21% 68.66% 24.95% -329.82% -189.55% 24.11% 49.52% 17.54% -293.24% 15.17% 12.80% 165.08% 222.19% 197.13% 216.70% 40.40% 22.41% 48.74% 38.57% 57.42% 118.88% 41.68%     
      qoq
    		-19.59% 146.23% -68.55% 89.77% -27.79% -52.32% -201.48% -208.30% 36.59% -17.39% -19.09% 11.23% 0.67% -16.90% 16.91% -12.88% -6.15% 58.89% -51.98% -12.96% 22.28% -168.56% -259.25% 26.32% -9.41% 26.11% -162.05% -275.07% 9.14% -0.87% 2.01% 4.34% 6.90% 132.97% 23.99% -3.77% 13.94% 3.28% 8.10% 16.93% 6.15% 17.32% 50.31% -24.31%  
      net income margin %
    		-31.45% -35.89% -15.45% -62.24% -30.85% -57.18% -83.87% 44.30% -174.71% -121.43% -193.65% -253.68% -294.86% -290.40% -352.02% -301.18% -422.82% -481.55% -107.40% -1139.82% -1084.00% -2228.99% 58.71% -4252.66% -6308.15% -6970.13% -5521.49% 60.09% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 
      net loss per common share - basic and diluted
    		-100 -160 -60  -42.5 -150 -330  -382.5 -370 -460 -790 -695 -810 -1,050 -930 -1,945 -2,620  -3,500 -352.5 -3,070   -325 -2,520                    
      weighted-average shares outstanding - basic and diluted
    		251,353,086,000 200,736,136,000 197,546,239,000   194,930,830,000 188,793,816,000   111,869,478,000 109,243,845,000 78,440,266,000  67,806,292,000 63,227,406,000 60,954,755,000  26,455,209,000  25,991,817,000  27,830,281,000    27,171,769,000                    
      comprehensive loss
    		-25,196,000 -31,333,000 -12,725,000  -7,606,750 -29,524,000 -61,925,000  -38,225,500 -41,250,000 -49,934,000 -61,718,000 -44,558,500 -54,913,000 -66,358,000 -56,963,000 -50,997,250 -69,386,000  -90,935,000 -9,774,500 -85,437,000   -8,722,250 -68,350,000                    
      loss on extinguishment of debt
    		    -13,308,750  -53,235,000                                       
      net income per common share - basic
    		   -210    360           -1,670    4,500 -2,840   -2,010                   
      net income per common share - diluted
    		   -210    340           -1,670    4,320 -2,840   -2,010                   
      weighted-average shares outstanding - basic
    		   196,127,948,000    169,258,564,000           26,225,073,000    27,665,728,000 27,519,229,000   26,968,818,000 26,842,785,000                  
      weighted-average shares outstanding - diluted
    		   196,127,948,000    189,641,251,000           26,225,073,000    28,854,445,000 27,519,229,000   26,968,818,000 28,449,767,000                  
      comprehensive income
    		   -40,455,000    61,022,000           -43,668,000    124,602,000 -78,263,000   -54,126,000 87,587,000                  
      other comprehensive income:
    		                                             
      unrealized gain on investments
    		          1,000 1,000 91,000 204,000         -9,000 -14,000 12,000 27,000 95,000     -112,000 -11,000 -56,000   497,000   20,000 3,000  3,000 5,989  
      other comprehensive loss:
    		                                             
      unrealized loss on investments
    		              -34,000 -232,000               -118,000        -21,000   -8,000    
      general and administrative
    		                        21,712,000 18,468,000 13,492,000 12,182,000 9,011,000 6,956,000 5,954,000 5,681,000 5,412,000 5,029,000 4,214,000 4,633,000 5,031,000 5,672,000 5,253,000 4,035,000 2,526,000 2,726,000 2,490,000 1,924,150 1,171,425 
      income (loss) from operations
    		                           86,929,000                  
      net income (loss) per common share - basic
    		                           3,260                  
      net income (loss) per common share - diluted
    		                           3,070                  
      unrealized gain (loss) on investments
    		                           208,000 216,000 187,000     -96,000 103,000  71,000        
      net loss per common share
    		                            -1,860 -1,710 -1,730 -1,860 -1,920 -1,800 -770 -620 -650 -570 -550 -560 -640 -600 -510 -0.34 -19.82 
      weighted-average shares outstanding
    		    187,181,856,000    103,106,616,000    66,407,242,000    28,902,507,000    27,473,873,000    27,090,284,000    26,804,026,000 26,786,796,000 26,605,189,000 24,311,844,000 22,591,326,000 22,563,152,000 22,550,438,000 22,541,455,000 22,532,031,000 22,494,075,000 22,465,175,000 20,589,293,000 15,432,641,000 15,399,018,000 15,369,055,000 15,253,704 349,170 
      total comprehensive loss
    		                            -49,695,000 -45,543,000 -46,248,000 -45,331,000 -43,348,000 -40,597,000 -17,498,000 -13,932,000 -14,088,000 -12,730,000 -12,416,000 -11,446,000 -9,803,000 -9,246,000 -7,871,000 -5,232,445  
      change in fair value of warrant liability
    		                                             
      grant income
    		                                             
      acquired in-process research and development
    		                                             
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 
                                                   
        assets
      		                                             
        current assets:
      		                                             
        cash and cash equivalents
      		156,158,000 92,447,000 86,061,000 114,633,000 144,761,000 144,717,000 189,304,000 226,609,000 82,248,000 114,833,000 138,470,000 144,911,000 124,775,000 159,399,000 122,940,000 150,364,000 208,892,000 103,672,000 219,186,000 217,939,000 304,962,000 215,748,000 298,489,000 149,386,000 166,130,000 211,978,000 274,344,000 174,836,000 26,755,000 24,380,000 30,823,000 21,024,000 20,373,000 19,867,000 47,140,000 48,768,000 37,207,000 80,824,000 129,787,000 208,641,000 40,232,000 47,944,000 48,638,000 71,895,828 16,626,859 
        accounts receivable
      		132,352,000 118,980,000 107,746,000 81,294,000 80,142,000 67,824,000 60,360,000 54,612,000 48,494,000 42,623,000 40,799,000 36,415,000 33,729,000 31,489,000 27,844,000 25,116,000 22,934,000 21,710,000 21,854,000                           
        inventories
      		104,209,000 108,539,000 114,466,000 99,322,000 94,491,000 80,102,000 84,469,000 73,095,000 65,623,000 51,435,000 45,676,000 39,352,000 35,201,000 29,545,000 29,232,000 35,654,000 34,394,000 33,972,000 23,714,000 20,030,000 16,136,000 9,061,000 8,248,000 1,841,000                      
        prepaid clinical development costs
      		5,791,000 2,791,000 4,170,000 504,000 586,000 499,000 349,000  193,000 3,049,000 2,863,000 6,916,000 1,026,000 2,199,000 373,000 698,000 1,138,000 986,000 650,000 443,000 844,000 1,110,000 890,000 1,189,000 6,081,000 5,653,000 3,977,000 4,392,000 7,411,000 7,650,000 2,864,000 1,630,000 2,554,000 4,786,000 1,732,000 1,121,000 1,430,000 1,963,000 550,000 1,053,000 894,000 1,330,000 1,257,000 503,394 212,612 
        prepaid inventory costs
      		54,928,000 33,299,000 24,772,000 18,210,000                                          
        other prepaid and current assets
      		6,023,000 4,408,000 5,380,000 4,815,000 18,018,000 14,413,000 10,626,000 11,290,000 4,507,000 6,287,000 4,317,000 5,584,000 9,866,000 9,211,000 9,184,000 10,849,000 11,173,000 10,328,000 9,770,000 34,163,000 23,954,000 16,884,000 11,497,000 11,354,000 3,924,000 2,758,000 792,000 923,000 1,581,000 1,060,000 1,321,000 1,822,000 986,000 1,343,000 1,634,000 789,000 1,154,000 1,286,000 381,000 665,000 724,000 265,000 320,000 535,716 70,907 
        total current assets
      		459,461,000 360,464,000 342,595,000 318,778,000 337,998,000 307,555,000 345,108,000 365,606,000 201,065,000 218,227,000 232,125,000 250,605,000 246,683,000 261,785,000 252,478,000 290,819,000 328,972,000 170,668,000 275,174,000 272,575,000 345,896,000 242,803,000 321,371,000 172,629,000 211,714,000 253,460,000 307,121,000 235,221,000 168,210,000 188,883,000 201,408,000 206,823,000 170,948,000 188,013,000 213,467,000 209,088,000 197,054,000 218,845,000 225,713,000 279,826,000 54,579,000 61,319,000 58,279,000 72,964,046 19,389,123 
        property and equipment
      		311,000 175,000 201,000 228,000 254,000 281,000 307,000 268,000  6,000 32,000 83,000 164,000 256,000 361,000 511,000 664,000 817,000 970,000 1,123,000 1,276,000 1,408,000 1,512,000 1,447,000 1,145,000 958,000 903,000 439,000 583,000 311,000 374,000 497,000 558,000 623,000 622,000 685,000 743,000 722,000 680,000 728,000 840,000 851,000 360,000 78,749 89,274 
        right of use operating lease assets
      		2,701,000 3,325,000 4,233,000 4,967,000 5,513,000 6,222,000 6,848,000 7,130,000 4,675,000 3,016,000 2,413,000 1,075,000 1,036,000 730,000 1,085,000 1,467,000 1,898,000 3,715,000 4,261,000 4,852,000 6,030,000 6,702,000 6,175,000 5,510,000 1,532,000 260,000 198,000 185,000                  
        intangible assets
      		56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000   56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 56,000 55,740 55,740 
        total assets
      		462,529,000 364,020,000 347,085,000 324,029,000 343,821,000 314,114,000 352,319,000 373,060,000 205,796,000 221,305,000 234,626,000 251,819,000 247,939,000 312,827,000 303,980,000 342,853,000 381,590,000 225,256,000 280,461,000 278,606,000 353,258,000 250,969,000 330,352,000 179,642,000 214,447,000 255,270,000 308,814,000 236,482,000 174,030,000 210,881,000 244,188,000 313,093,000 185,242,000 214,612,000 263,791,000 277,466,000 286,036,000 306,394,000 315,958,000 325,221,000 60,530,000 69,287,000 70,223,000 86,575,812 19,534,137 
        liabilities and stockholders’ deficit
      		                                             
        current liabilities:
      		                                             
        accounts payable
      		68,406,000 77,513,000 74,704,000 71,994,000 51,650,000 34,864,000 47,669,000 28,433,000 31,718,000 26,214,000 24,558,000 17,065,000 23,040,000 18,580,000 12,832,000 26,829,000 17,559,000 20,745,000 29,353,000 30,342,000 51,975,000 17,584,000 29,690,000 15,114,000 28,856,000 23,735,000 28,404,000 33,270,000 18,630,000 22,482,000 11,962,000 19,503,000 18,714,000 11,636,000 1,783,000 1,566,000 1,540,000 1,979,000 3,305,000 2,899,000 3,299,000 4,211,000 2,098,000 1,944,604 1,655,762 
        accrued clinical development costs
      		2,677,000 1,619,000 1,209,000 7,071,000 5,035,000 3,546,000 3,419,000 3,046,000 3,441,000 3,454,000 5,569,000 4,617,000 5,426,000 3,996,000 11,420,000 3,652,000 7,013,000 3,746,000 2,873,000 7,549,000 7,663,000 21,686,000 19,641,000 22,687,000 17,511,000 20,954,000 17,301,000 18,871,000 20,030,000 9,524,000 15,440,000 11,000,000 8,264,000 6,371,000 2,447,000 2,505,000 1,401,000 963,000 1,015,000 1,958,000 929,000 360,000 526,000 449,976 923,809 
        accrued variable consideration
      		85,811,000 78,508,000 61,299,000 56,005,000 56,535,000 52,003,000 44,851,000 34,518,000 34,284,000 31,102,000 25,090,000                                   
        other accrued liabilities
      		17,489,000 18,641,000 15,455,000 16,625,000 19,593,000 19,247,000 23,294,000 23,140,000 24,998,000 19,284,000 12,851,000 34,421,000 35,191,000 35,395,000 30,066,000 30,200,000 30,410,000 34,476,000 31,673,000 48,766,000 24,790,000 21,458,000 21,908,000 23,570,000 11,871,000 9,944,000 4,809,000 3,774,000 3,625,000 2,806,000 2,043,000 3,015,000 2,253,000 1,861,000 2,248,000 1,908,000 1,423,000 2,308,000 1,282,000 1,052,000 1,150,000 885,000 564,000 948,376 1,212,666 
        royalty sale liability
      		80,746,000 94,826,000 66,312,000 57,237,000 47,586,000 38,394,000 32,754,000                                       
        deferred revenue from collaborations
      		43,531,000 30,679,000 22,313,000 4,542,000 8,518,000 15,078,000 20,672,000 29,350,000 25,402,000 19,723,000 15,634,000 12,157,000 3,507,000 4,045,000 5,028,000 3,795,000 5,683,000 3,068,000 3,930,000 2,543,000 1,662,000 1,662,000 1,134,000 1,170,000 2,152,000 2,618,000 3,599,000 3,926,000                  
        operating lease liabilities
      		1,699,000 2,384,000 2,738,000 2,822,000 2,741,000 2,741,000 2,679,000 2,539,000 1,553,000 918,000 687,000 305,000 384,000 693,000 957,000 1,217,000 1,392,000 2,402,000 2,346,000 2,340,000 2,587,000 2,631,000 2,232,000 1,913,000 454,000 267,000 199,000 184,000                  
        total current liabilities
      		300,359,000 359,033,000 298,796,000 270,966,000 246,233,000 165,873,000 175,338,000 164,512,000 156,224,000 137,708,000 107,173,000 95,486,000 92,308,000 82,345,000 82,275,000 79,085,000 73,352,000 78,485,000 82,644,000 97,893,000 94,069,000 75,947,000 83,881,000 73,453,000 66,080,000 57,518,000 54,312,000 60,025,000 42,285,000 34,964,000 30,048,000 34,997,000 30,995,000 21,605,000 8,160,000 7,635,000 5,993,000 6,828,000 7,029,000 6,939,000 5,631,000 5,456,000 3,188,000 3,342,956 6,644,425 
        convertible notes, net of issuance costs
      		97,394,000 54,863,000 54,766,000 54,670,000 54,575,000 262,922,000 262,475,000 262,033,000 261,596,000 261,165,000 260,738,000 260,316,000 259,899,000 259,487,000 259,080,000 258,678,000 258,280,000 272,508,000 272,098,000 271,694,000 179,367,000                         
        long-term debt
      		152,674,000 151,653,000 146,452,000 141,449,000 140,971,000                            140,000 585,000 1,451,000 1,871,000 2,283,000 3,084,000 3,473,000 3,855,000 4,676,000 4,922,000    
        other long-term liabilities
      		8,739,000 7,436,000 7,436,000               1,290,000 1,290,000 1,290,000 1,290,000 1,710,000                        
        total liabilities
      		770,460,000 815,381,000 780,594,000 750,240,000 732,543,000 684,323,000 696,539,000 667,358,000 660,790,000 631,309,000 606,604,000 581,482,000 571,717,000 606,927,000 595,678,000 591,893,000 578,534,000 587,961,000 584,771,000 548,000,000 449,392,000 242,009,000 244,863,000 229,888,000 194,497,000 186,758,000 179,480,000 61,472,000 42,285,000 34,964,000 30,048,000 34,997,000 31,135,000 22,190,000 9,611,000 9,506,000 8,276,000 9,912,000 10,502,000 10,794,000 10,307,000 10,378,000 3,188,000 3,342,956 6,644,425 
        commitments and contingencies
      		                                             
        stockholders’ deficit:
      		                                             
        preferred stock, 0.001 par value...
      		                                             
        common stock, 0.001 par value...
      		257,000 205,000 200,000 197,000 196,000 195,000 195,000 188,000 118,000 112,000 101,000 87,000 75,000 72,000 65,000 61,000 61,000 27,000 26,000 26,000 26,000 28,000 28,000 28,000 27,000 27,000 27,000 27,000 27,000 27,000 27,000 26,000 23,000 23,000 23,000 23,000 23,000 23,000 22,000 22,000 15,000 15,000 15,000 15,357 396 
        additional paid-in capital
      		1,395,717,000 1,288,974,000 1,275,498,000 1,270,074,000 1,267,109,000 1,264,305,000 1,260,770,000 1,248,774,000 1,149,170,000 1,137,822,000 1,134,609,000 1,127,004,000 1,071,183,000 1,045,468,000 992,964,000 969,268,000 964,401,000 733,524,000 722,534,000 713,782,000 797,655,000 743,273,000 734,365,000 723,232,000 715,166,000 701,794,000 694,266,000 685,816,000 670,340,000 664,817,000 657,497,000 636,821,000 467,504,000 462,471,000 454,379,000 450,661,000 446,529,000 437,548,000 433,793,000 430,348,000 145,187,000 144,064,000 142,954,000 141,585,222 796,508 
        treasury stock
      		-54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000 -54,998,000                         
        accumulated deficit
      		-1,648,907,000 -1,685,542,000 -1,654,209,000 -1,641,484,000 -1,601,029,000 -1,579,711,000 -1,550,187,000 -1,488,262,000 -1,549,284,000 -1,492,940,000 -1,451,690,000 -1,401,755,000 -1,340,036,000 -1,284,549,000 -1,229,432,000 -1,163,108,000 -1,106,377,000 -1,041,258,000 -971,872,000 -928,204,000 -838,817,000 -734,341,000 -648,904,000 -773,515,000 -695,266,000 -633,320,000 -564,943,000                   
        total stockholders’ deficit
      		-307,931,000 -451,361,000 -433,509,000 -426,211,000  -370,209,000 -344,220,000 -294,298,000  -410,004,000 -371,978,000 -329,663,000  -294,100,000 -291,698,000 -249,040,000  -362,705,000 -304,310,000 -269,394,000                          
        total liabilities and stockholders’ deficit
      		462,529,000 364,020,000 347,085,000 324,029,000  314,114,000 352,319,000 373,060,000  221,305,000 234,626,000 251,819,000  312,827,000 303,980,000 342,853,000  225,256,000 280,461,000 278,606,000                          
        liabilities and stockholders' deficit
      		                                             
        revenue interest liability
      		       43,486,000 34,828,000 37,013,000 22,784,000 26,921,000 24,760,000 19,636,000 21,972,000 13,392,000 11,295,000 14,048,000 12,469,000 6,353,000 5,392,000 10,926,000 9,276,000 8,999,000 5,236,000 128,420,000 124,409,000                   
        accumulated other comprehensive loss
      		           -1,000 -2,000 -93,000 -297,000 -263,000 -31,000          -16,000                   
        total stockholders' deficit
      		    -388,722,000    -454,994,000    -323,778,000    -196,944,000                             
        total liabilities and stockholders' deficit
      		    343,821,000    205,796,000    247,939,000    381,590,000                             
        liabilities and stockholders’ equity
      		                                             
        stockholders’ equity:
      		                                             
        accumulated other comprehensive income
      		                       9,000  11,000         22,000 118,000 15,000 11,000   2,000 5,000 3,000 5,989  
        short-term investments
      		           17,427,000 42,086,000 29,942,000 62,905,000 68,138,000 50,441,000      2,247,000 7,931,000 34,651,000 31,883,000 26,882,000 53,692,000 132,463,000 155,793,000 166,400,000 182,347,000 147,035,000 162,017,000 162,961,000 158,410,000 157,263,000 134,772,000 94,995,000 69,467,000 12,729,000 11,780,000 8,064,000   
        liabilities and stockholders' equity
      		                                             
        stockholders’ (deficit) equity:
      		                                             
        restricted cash
      		             50,000,000 50,000,000 50,000,000 50,000,000 50,000,000      928,000 928,000 928,000 928,000 1,193,000                  
        accumulated other comprehensive gain
      		                        23,000                     
        total stockholders' (deficit) equity
      		                    -96,134,000                         
        total liabilities and stockholders' (deficit) equity
      		                    353,258,000                         
        other long-term assets
      		                     56,000 1,294,000                       
        total stockholders’ equity
      		                     8,960,000 85,489,000 -50,246,000  68,512,000 129,334,000 175,010,000 131,745,000 175,917,000 214,140,000 278,096,000 154,107,000 192,422,000 254,180,000 267,960,000 277,760,000 296,482,000 305,456,000 314,427,000 50,223,000 58,909,000 67,035,000   
        total liabilities and stockholders’ equity
      		                     250,969,000 330,352,000 179,642,000  255,270,000 308,814,000 236,482,000 174,030,000 210,881,000 244,188,000 313,093,000 185,242,000 214,612,000 263,791,000 277,466,000 286,036,000 306,394,000 315,958,000 325,221,000 60,530,000 69,287,000 70,223,000   
        long-term investments
      		                            5,181,000 21,631,000 42,350,000 105,717,000 13,680,000 25,920,000 49,646,000 67,637,000 88,183,000 86,771,000 89,509,000 44,611,000 5,055,000 7,061,000    
        total stockholders' equity
      		                        19,950,000                     
        total liabilities and stockholders' equity
      		                        214,447,000                     
        current portion of long-term debt
      		                             152,000 603,000 1,479,000 1,764,000 1,737,000 1,682,000 1,656,000 1,629,000 1,578,000 1,427,000 1,030,000 253,000     
        investments
      		                                          11,528,000 13,477,277  
        deficit accumulated during the development stage
      		                                             
        assets held for sale
      		                                           29,108 29,108 
        liabilities, convertible preferred stock and stockholders’ deficit
      		                                             
        short term borrowings with related parties, net of debt discount
      		                                             
        accrued interest
      		                                             
        warrant liabilities
      		                                            2,852,188 
        convertible preferred stock:
      		                                             
        series a preferred stock par value 0.001; no shares authorized, issued or outstanding as of september 30, 2013; 34,785,000 shares authorized and 23,975,000 shares issued and outstanding at december 31, 2012, aggregate liquidation preference of 23,975,000 at december 31, 2012
      		                                             
        total stockholders’ (deficit) equity
      		                                           83,232,856  
        total liabilities, convertible preferred stock and stockholders’ (deficit) equity
      		                                           86,575,812 19,534,137 
        deferred offering costs
      		                                            2,449,637 
        series a preferred stock par value 0.001; 59,538,092 shares authorized as of june 30, 2013 and 34,785,000 shares authorized as of december 31, 2012, 57,598,092 shares issued and outstanding at june 30, 2013 and 23,975,000 shares issued and outstanding at december 31, 2012, aggregate liquidation preference of 57,598,092 at june 30, 2013 and 23,975,000 at december 31, 2012
      		                                            57,478,555 
        series a-1 preferred stock par value 0.001; 7,862,283 shares authorized as of june 30, 2013 and december 31, 2012, 6,750,000 shares issued and outstanding at june 30, 2013 and 0 shares issued and outstanding at december 31, 2012, aggregate liquidation preference of 7,803,000 at june 30, 2013 and 0 at december 31, 2012
      		                                            7,749,531 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 
                                                    
          operating activities
        		                                            
          net loss
        		-25,196,000 -31,333,000   -21,318,000 -29,524,000   -56,344,000 -41,250,000 -49,935,000 -61,719,000 -55,487,000 -55,117,000 -66,324,000 -56,731,000 -65,119,000   -90,935,000 -104,476,000    -61,946,000    -49,911,000 -45,730,000 -46,130,000 -45,219,000 -43,337,000 -40,541,000 -17,402,000 -14,035,000 -14,585,000 -12,801,000 -12,395,000 -11,466,000 -9,806,000 -9,238,000 -7,874,000 -5,238,434 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                            
          non-cash royalty revenue
        		-18,481,000 -16,359,000 -13,580,000 -10,481,000 -9,686,000 -8,860,000                                       
          depreciation expense
        		27,000 26,000 27,000 26,000 27,000 26,000   6,000 26,000 51,000 81,000 92,000 105,000 150,000 153,000 153,000 153,000 153,000 153,000 160,000 163,000 118,000 106,000 101,000 92,000 55,000 71,000 67,000 63,000 61,000 62,000 65,000 69,000 63,000 63,000 64,000 54,000 56,000 59,000 51,000 41,000 12,000 10,525 
          amortization of debt issuance costs and discounts
        		589,000 847,000 820,000 699,000                                         
          non-cash interest expense related to the royalty sale liability
        		13,894,000 14,637,000 13,273,000 13,090,000 12,673,000                                        
          stock-based compensation expense
        		2,502,000 2,349,000 2,669,000 2,465,000 2,805,000 3,022,000 2,931,000 3,235,000 2,920,000 2,975,000 3,160,000 2,903,000 3,715,000 3,537,000 3,527,000 4,436,000 4,474,000 5,497,000 8,584,000 5,751,000 6,673,000 7,264,000 7,395,000 7,053,000 6,358,000 6,327,000 6,563,000 6,636,000 5,495,000 5,723,000 5,921,000 4,941,000 4,980,000 4,150,000 3,709,000 4,121,000 4,556,000 3,371,000 2,898,000 2,072,000 950,000 935,000 741,000 519,832 
          changes in assets and liabilities:
        		                                            
          accounts receivable
        		7,838,000 -11,234,000 -26,452,000 -1,152,000 -12,318,000 -7,464,000 -5,748,000 -6,118,000 -5,871,000 -1,824,000 -4,384,000 -2,686,000 -2,240,000 -3,645,000 -2,728,000 -2,182,000 -1,224,000 144,000                           
          prepaids and other assets
        		-17,338,000 -6,176,000 -10,793,000 -4,925,000 -3,692,000 -3,937,000 315,000 -6,590,000 4,636,000 -2,156,000 5,320,000 -1,608,000 518,000 -1,853,000 1,990,000 764,000 -997,000 -894,000 11,798,000 -9,808,000 -6,804,000 -5,607,000 156,000 -2,538,000 -1,594,000 -3,642,000 546,000 1,294,000                 
          inventories
        		915,000 5,927,000 -15,144,000 -4,831,000 -14,389,000 4,367,000 -11,374,000 -7,472,000 -14,188,000 -5,759,000 -6,324,000 -4,151,000 -5,656,000 -313,000 6,422,000 -1,260,000 -422,000 -10,258,000 -3,684,000 -3,894,000 -7,075,000 -813,000 -6,407,000 -1,841,000                     
          deferred revenue
        		9,054,000 8,366,000 17,771,000 -3,976,000 -6,560,000 -5,594,000 -8,678,000 3,948,000 5,679,000 4,089,000 3,477,000 8,650,000 -538,000 -1,194,000 1,022,000 -2,100,000 2,404,000 -1,074,000 2,444,000 881,000 0 528,000 -36,000 -982,000 -466,000 -981,000 -982,000 4,581,000                 
          accounts payable
        		3,338,000 2,901,000 2,618,000 27,844,000 9,304,000 -12,770,000 19,348,000 -3,450,000 5,504,000 1,656,000 7,493,000 -5,975,000 4,474,000 5,769,000 -14,033,000 9,393,000 -3,266,000 -8,651,000 -599,000 -21,583,000 34,432,000 -12,247,000 14,571,000 -13,650,000 5,103,000 -4,453,000      787,000 7,081,000 7,038,000 217,000 26,000 833,000  452,000 813,000 -738,000   1,011,405 
          other accrued liabilities
        		-4,864,000 21,183,000 -1,748,000 -932,000 6,347,000 12,978,000 1,138,000 -2,121,000 8,195,000 10,573,000 4,578,000 -1,249,000 1,229,000 -1,791,000 7,628,000 -3,049,000 -789,000 4,445,000 -21,772,000 25,042,000 -11,102,000 1,606,000 -4,399,000 16,656,000 -1,614,000 9,028,000 -768,000 3,354,000 11,096,000 -5,153,000 5,761,000 3,389,000   281,000     76,000    -239,365 
          net cash from operating activities
        		-27,722,000 -4,286,000 -31,422,000 -22,628,000 -34,952,000 -35,325,000 -7,205,000 53,828,000 -37,056,000 -19,325,000 -24,750,000 -54,356,000 -42,472,000 -42,833,000 -50,532,000 -38,990,000 -57,706,000 -69,169,000 -47,866,000 -89,068,000 -68,550,000 -86,671,000 139,391,000 -69,347,000 -49,994,000 -58,029,000 -54,009,000 91,691,000                 
          capital expenditures
        		-189,000 0 0  0 -167,000 -105,000 122,000 0 0 0 0 0 0 0 0 0 0 0  -176,000 225,000 -987,000 217,000 -56,000 -569,000 0 0                 
          free cash flows
        		-27,911,000 -4,286,000 -31,422,000  -34,952,000 -35,492,000 -7,310,000 53,950,000 -37,056,000 -19,325,000 -24,750,000 -54,356,000 -42,472,000 -42,833,000 -50,532,000 -38,990,000 -57,706,000 -69,169,000 -47,866,000  -68,726,000 -86,446,000 138,404,000 -69,130,000 -50,050,000 -58,598,000 -54,009,000 91,691,000                 
          investing activities
        		                                            
          purchase of property and equipment
        		-189,000     -167,000 -77,000 -73,000             -176,000 83,000 -585,000 -191,000 -172,000 -358,000                   
          net cash from investing activities
        		-189,000    0 -167,000 -77,000 -73,000 0 0 17,500,000 25,000,000 -11,794,000 33,000,000 5,000,000 -18,102,000     -12,676,000 2,333,000 5,110,000 26,589,000 -2,868,000 -5,313,000       27,103,000 16,168,000       785,000 347,000 1,153,000  
          financing activities
        		                                            
          proceeds from exercise of warrants, net of issuance costs
        		16,217,000     0 9,042,000 5,766,000                                     
          payment of issuance costs
        		 0 0 -7,500,000          0 0 -219,000                             
          net cash from financing activities
        		16,217,000 10,672,000 2,850,000 -7,500,000 34,996,000 -9,095,000 -30,023,000 90,606,000 4,471,000 -4,312,000 809,000 49,492,000 -30,358,000 46,292,000 18,108,000 -1,436,000 213,410,000 3,655,000 49,113,000 2,045,000 170,440,000 1,597,000 3,674,000 26,014,000 7,014,000 976,000    1,185,000 9,293,000         190,414,000 134,000 5,037,000 52,000 73,431,885 
          net decrease in cash and cash equivalents
        		-11,694,000             36,459,000 -27,424,000 -58,528,000    -87,023,000                         
          cash and cash equivalents at beginning of period
        		167,852,000 0 0 144,761,000  0 0 82,248,000                 0 0 0 36,973,000 0 0 34,468,000 0 0 38,165,000 0 0 77,336,000 0 0 85,038,000 0 0 56,537,000 0 
          cash and cash equivalents at end of period
        		156,158,000 6,386,000 -28,572,000 114,633,000 44,000 -44,587,000 -37,305,000 226,609,000                     2,375,000 -6,443,000 30,823,000 651,000 506,000 19,867,000 -1,628,000 11,561,000 37,207,000 -48,963,000 -78,854,000 208,641,000 -7,712,000 -694,000 48,638,000 55,268,969 
          supplemental disclosure of cash flow information:
        		                                            
          non-cash right of use asset
        		27,000 9,000 -10,000 30,000 18,000 -4,000                                       
          non-cash loss on extinguishment of debt
        		     0                                       
          paid-in-kind interest on long-term debt
        		 4,580,000                                           
          non-cash interest expense related to the revenue interest liability
        		    0 0 10,632,000 10,937,000 11,976,000 11,918,000 11,465,000 11,320,000 11,267,000 11,095,000 11,213,000 11,015,000 10,597,000 10,445,000 7,940,000 4,925,000 5,821,000 4,928,000 4,640,000 4,171,000 4,124,000                    
          other long-term liabilities
        		 0                   -420,000                        
          payments on revenue interest liability
        		    0 0 0 -5,832,000 -4,598,000 -4,292,000 -3,510,000 -3,106,000 -2,346,000 -2,360,000 -2,101,000 -1,217,000 -1,126,000 -1,108,000 -582,000 -573,000 -390,000 -46,000                       
          repurchase of revenue interest liability
        		     0                                       
          payment of royalty sale liability issuance costs
        		    0                                        
          proceeds from royalty sale liability
        		    0 0                                       
          proceeds from issuance of common stock, net of issuance costs
        		     0 0 90,672,000                              0 -168,000 190,150,000     
          proceeds from issuance of common stock from atm program, net of issuance costs
        		 10,531,000   -18,000    0 -31,000   21,988,000 48,652,000                               
          proceeds from exercise of common stock options
        		     0           551,000 375,000 168,000 2,668,000 239,000 1,643,000 3,738,000 1,014,000 7,014,000 1,201,000 1,887,000 1,669,000 27,000 1,636,000 9,738,000 410,000 55,000 267,000 10,000 8,000 27,000 379,000 534,000 264,000 165,000 90,000 52,000  
          net increase in cash and cash equivalents
        		 6,386,000 -28,572,000 -30,128,000 44,000 -44,587,000 -37,305,000 144,361,000   -6,441,000 20,136,000      -65,514,000    -82,741,000 148,175,000 -16,744,000  -62,366,000              123,603,000    55,268,969 
          common stock issuance costs not yet paid
        		 11,000                                           
          royalty sale issuance costs not yet paid
        		                                            
          purchase of property and equipment not yet paid
        		      -28,000 195,000              142,000 -402,000 408,000 116,000 -211,000                   
          net income
        		   -40,455,000    61,022,000               124,611,000 -78,249,000   -54,221,000 87,379,000                 
          adjustments to reconcile net income to net cash from operating activities:
        		                                            
          non-cash loss on extinguishment of debt and exchange transaction
        		                                            
          accretion and amortization of premiums and discounts on investments
        		                                            
          purchases of investments
        		            -41,795,000 0 0 -18,102,000     0 0 0 -4,420,000 -7,696,000                    
          proceeds from sales/maturities of investments
        		        0 0 17,500,000 25,000,000 30,001,000 33,000,000       0 2,250,000 5,695,000 31,200,000 5,000,000 21,675,000 26,950,000 45,885,000 45,015,000 37,490,000 44,903,000 48,681,000 35,686,000 44,373,000 63,974,000 61,633,000 40,290,000 36,875,000 27,182,000 12,813,000 1,000,000 2,500,000 4,426,000  
          purchases of property and equipment
        		                                            
          repurchase or principal payment of revenue interest liability
        		                                            
          proceeds from credit agreement, net of issuance costs
        		                                            
          proceeds from issuance of convertible notes, net of issuance costs
        		                                            
          repayment of convertible notes
        		                                            
          proceeds from issuance of common stock and warrants from offering, net of issuance costs
        		                                            
          proceeds from exercise of warrants
        		                                            
          other financing activities
        		                                            
          cash, cash equivalents and restricted cash at beginning of period
        		        0 0 0 124,775,000 0 0 0 258,892,000  0 0 304,962,000  0 0 167,058,000                     
          issuance costs not yet paid
        		                                            
          amortization of premiums and discounts on investments
        		        0 0 -73,000 -339,000 -260,000 167,000 199,000 173,000                63,000 103,000 148,000 274,000 238,000 254,000 218,000 151,000 27,000 54,000 53,000 53,000  
          amortization of debt issuance costs
        		     447,000 442,000 437,000  427,000 422,000 417,000  407,000 402,000 398,000  410,000 404,000 400,000            3,000 3,000 4,000 5,000 6,000 7,000 8,000 8,000 8,000    0 
          proceeds from issuance of common stock, warrants, and pre-funded warrants, net of issuance costs
        		         0 -170,000 52,598,000                                 
          proceeds from exercise of pre-funded warrants
        		        0 11,000                                   
          non cash right of use asset
        		       72,000  26,000 35,000 1,000 -3,000 -4,000 6,000 6,000 -17,000 4,000 2,000 4,000 17,000 10,000 -98,000 91,000 0 5,000 1,000 25,000                 
          amortization of discount and issuance costs on convertible notes
        		                                            
          repayment of principal on revenue interest liability
        		                                            
          payment for other issuance costs
        		                                            
          net decrease in cash, cash equivalents and restricted cash
        		                                            
          cash, cash equivalents and restricted cash at end of period
        		         -23,637,000 -6,441,000 144,911,000 -84,624,000 36,459,000 -27,424,000 200,364,000 105,220,000 -65,514,000 1,247,000 217,939,000 89,214,000 -82,741,000 148,175,000 150,314,000 -45,848,000 -62,366,000 99,243,000 176,029,000                 
          common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid
        		           170,000                                 
          gain on extinguishment of convertible debt
        		                                            
          proceeds from revenue interest liability, net of issuance costs
        		                0 0       0 -225,000                   
          payment for debt issuance costs on convertible notes
        		                                            
          debt issuance costs not yet paid
        		                   445,000                         
          acquired in-process research and development
        		                                            
          purchases of in-process research and development
        		                                            
          proceeds from issuance of convertible notes
        		                                            
          prepayment of forward stock repurchase transaction
        		                                            
          purchase of capped call options associated with convertible notes
        		                                            
          payment for debt issuance costs, debt-to-equity conversion
        		                                            
          net increase in cash, cash equivalents
        		                                            
          cash, and cash equivalents and restricted cash at beginning of period
        		                                            
          offering costs not yet paid
        		                                       173,000     
          accretion of premiums and discounts on investments
        		                    0 -4,000 -20,000 -73,000  -19,000                   
          payment of debt issuance costs
        		                 0 -390,000 -50,000                         
          other long-term assets
        		                                            
          proceeds from revenue interest liability
        		                     0 0 25,000,000                     
          payment for debt issuance costs
        		                                            
          payments on long-term debt
        		                                            
          net increase in cash, cash equivalents and restricted cash
        		                                            
          issuance costs from revenue interest agreement not yet paid
        		                                            
          net cash provided by investing activities
        		                           45,696,000  31,570,000 30,283,000              
          net cash provided by financing activities
        		                           1,669,000          126,000       
          net increase (decrease) in cash and cash equivalents
        		                           139,056,000                 
          amortization of debt discount
        		                               2,000 3,000 4,000 5,000 6,000 6,000 7,000 7,000 8,000     
          net cash (used in) provided by investing activities
        		                                            
          (gain) on sale of assets
        		                                            
          proceeds from sale of assets
        		                                     3,000   0   135,000 
          net cash (used in) provided by financing activities
        		                                            
          net (decrease) increase in cash and cash equivalents
        		                                            
          loss related to assets held for sale
        		                                        0 23,000 6,000 0 
          loss on sale of assets
        		                                        0 -10,000 11,000  
          proceeds from warrant issuance
        		                                        0    
          proceeds from debt issuance, net of issuance costs
        		                                        -31,000    
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                            
          amortization of debt discount and beneficial conversion feature
        		                                            
          revaluation of warrants
        		                                            
          noncash interest expense on convertible notes
        		                                           0 
          proceeds from issuance of preferred stock, net of issuance costs
        		                                           -2,759 
          conversion of convertible promissory notes, including accrued interest of 923 into series a preferred stock
        		                                            
          conversion of convertible long-term pfizer note, including accrued interest of 274 into series a-1 preferred stock
        		                                            
          deferred offering costs not yet paid
        		                                            
          payments for offering costs in connection with initial public offering
        		                                            
          amortization of debt discount and beneficial conversion
        		                                           0 
          write-off of acquired in-process research and development
        		                                            
          common stock issued in license agreement
        		                                            
          cash obtained in stock acquisition
        		                                            
          other investing
        		                                            
          proceeds from initial public offering, net of issuance costs
        		                                            
          proceeds from debt issuance with related parties
        		                                            
          gain on sale of assets
        		                                            
          conversion of convertible promissory notes, including accrued interest of 923,092 into series a preferred stock
        		                                           0 
          conversion of convertible long-term pfizer note, including accrued interest of 274,155 into series a-1 preferred stock
        		                                           0 
          initial public offering costs not yet paid
        		                                            
          change in fair of warrant liability
        		                                            
          purchases of short-term investments
        		                                            
          proceeds from maturities of short-term investments
        		                                            
          proceeds from issuance of common stock